Market Closed -
Nyse
04:00:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
0.1749
USD
|
-4.58%
|
|
-2.24%
|
-19.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
369.4
|
271.5
|
218.4
|
108.4
|
46.97
|
43.87
|
-
|
-
|
Enterprise Value (EV)
1 |
369.4
|
271.5
|
218.4
|
108.4
|
46.97
|
43.87
|
43.87
|
43.87
|
P/E ratio
|
-17.5
x
|
-11.3
x
|
-9.18
x
|
-5
x
|
-1.97
x
|
-1.59
x
|
-1.59
x
|
-1.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4,113
x
|
1,715
x
|
6,553
x
|
34
x
|
42.9
x
|
-
|
-
|
-
|
EV / Revenue
|
4,113
x
|
1,715
x
|
6,553
x
|
34
x
|
42.9
x
|
-
|
-
|
-
|
EV / EBITDA
|
-19,739,195
x
|
-11,324,598
x
|
-8,918,203
x
|
-4,470,880
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-25,481,365
x
|
-15,627,904
x
|
-14,105,674
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
162,740
|
199,642
|
216,248
|
216,865
|
217,265
|
250,816
|
-
|
-
|
Reference price
2 |
2.270
|
1.360
|
1.010
|
0.5000
|
0.2162
|
0.1749
|
0.1749
|
0.1749
|
Announcement Date
|
3/9/20
|
3/29/21
|
3/8/22
|
3/15/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.0898
|
0.1583
|
0.0333
|
3.188
|
1.096
|
-
|
-
|
-
|
EBITDA
|
-18.72
|
-23.98
|
-24.49
|
-24.25
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.92
|
-24.21
|
-24.73
|
-24.59
|
-23.77
|
-27.04
|
-34.74
|
-35.98
|
Operating Margin
|
-21,067.85%
|
-15,288.67%
|
-74,211.7%
|
-771.33%
|
-2,168.43%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.37
|
-22.45
|
-23.28
|
-21
|
-22.94
|
-26.94
|
-34.62
|
-35.83
|
Net income
1 |
-18.3
|
-23.24
|
-23.68
|
-21
|
-22.94
|
-26.94
|
-34.62
|
-35.83
|
Net margin
|
-20,372.8%
|
-14,678.38%
|
-71,044.73%
|
-658.63%
|
-2,093.25%
|
-
|
-
|
-
|
EPS
2 |
-0.1300
|
-0.1200
|
-0.1100
|
-0.1000
|
-0.1100
|
-0.1100
|
-0.1100
|
-0.1050
|
Free Cash Flow
|
-14.5
|
-17.37
|
-15.48
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-16,142.6%
|
-10,973.02%
|
-46,456.17%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/29/21
|
3/8/22
|
3/15/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
1.062
|
1.062
|
1.063
|
1.096
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-6.816
|
-6.649
|
-7.653
|
-5.84
|
-5.373
|
-5.387
|
-5.493
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.878
|
-6.714
|
-7.722
|
-5.925
|
-5.463
|
-5.48
|
-5.586
|
-6.159
|
-6.134
|
-5.887
|
-5.75
|
-5.75
|
-6.75
|
-7.75
|
Operating Margin
|
-
|
-
|
-
|
-557.69%
|
-514.13%
|
-515.49%
|
-509.67%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.837
|
-6.699
|
-5.978
|
-5.923
|
-5.462
|
-3.635
|
-5.513
|
-6.06
|
-6.055
|
-5.314
|
-5.7
|
-5.7
|
-6.7
|
-7.7
|
Net income
1 |
-6.837
|
-6.699
|
-5.978
|
-5.923
|
-5.462
|
-3.635
|
-5.513
|
-6.06
|
-6.055
|
-5.314
|
-5.7
|
-5.7
|
-6.7
|
-7.7
|
Net margin
|
-
|
-
|
-
|
-557.42%
|
-514.03%
|
-341.91%
|
-503.01%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0300
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0200
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0250
|
-0.0300
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/8/22
|
5/12/22
|
8/11/22
|
11/2/22
|
3/15/23
|
5/10/23
|
8/9/23
|
11/8/23
|
3/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-14.5
|
-17.4
|
-15.5
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.41
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
451.62%
|
3.63%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/29/21
|
3/8/22
|
3/15/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
0.1749
USD Average target price
0.8667
USD Spread / Average Target +395.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.10% | 43.87M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|